Publicaciones científicas

Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats

C. Marín (1, 3, 5), E. Aguilar (1), M. C. Rodríguez-Oroz (2, 3), G. D. Bartoszyk (4) and J. A. Obeso (2, 3)
(1) Laboratori de Neurologia Experimental, Institut d?Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
(2) Department of Neurology and Neurosurgery, Neuroscience Center, Clínica Universitaria and Medical School, University of Navarra and CIMA, Pamplona, Spain
(3) Centro de Investigación en Redes sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain
(4) Preclinical Research, Merck Serono, Darmstadt, Germany
(5) Laboratori de Neurología, Servei de Neurologia, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain

Revista: Psychopharmacology

Fecha: 01-jun-2009

Neurología

RATIONALE
Dyskinesia affects the majority of levodopa-treated parkinsonian patients within 5-10 years of treatment with levodopa. Clinical and preclinical observations suggest that an increase in serotoninergic transmission can contribute to the appearance of dyskinesias. It is thus conceivable that a modulation of synaptic dopamine (DA) levels induced by the inhibition of serotonin (5-HT) release, as a consequence of 5-HT(1A) agonists administration, might alleviate dyskinesias.

OBJECTIVE
Since 5-HT(1A) receptors are expressed in the subthalamic nucleus (STN), the aim of the present study was to assess the effect of the intrasubthalamic administration of sarizotan, a compound with full 5-HT(1A) agonist properties, on levodopa-induced dyskinesias in the 6-hydroxydopamine (6-OHDA) model of parkinsonism.

MATERIALS AND METHODS
Male Sprague-Dawley rats received a unilateral 6-OHDA administration in the nigrostriatal pathway. A test of apomorphine was performed to evaluate dopamine depletion. One week later, a cannula was implanted in the STN. Animals were treated with levodopa (6 mg/kg, i.p., twice at day) for 22 consecutive days. On day 23, several doses (1 ng, 10 ng, or 1 microg) of sarizotan were administered through the cannula to the STN. The higher doses of sarizotan effectively attenuated all levodopa-induced dyskinesias including axial, limb, and orolingual subtypes.

CONCLUSIONS
These results suggest that the STN is a target structure for the antidyskinetic action of sarizotan and indicate that drug-mediated modulation of STN activity may be an alternative option for the treatment of levodopa-induced dyskinesias in Parkinson's disease.

CITA DEL ARTÍCULO Psychopharmacology (Berl). 2009 Jun;204(2):241-50

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra